Descriptions

In Saccharomyces cerevisiae, RING domain-containing Ub ligase UBR1 recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. Binding of dipeptides with destabilizing N-terminal residues to two substrate-binding sites of UBR1 causes dissociation of the C-terminal autoinhibitory domain of UBR1 from its N-terminal region that contains all three substrate-binding sites. This dissociation allows the interaction between UBR1 and CUP9, a transcriptional repressor of the peptide transporter PTR2, thereby accelerating the UBR1-dependent degradation of CUP9 and increasing the cell's capacity to import peptides. An aspect of autoinhibition characteristic of yeast UBR1 also is observed with mouse UBR1.

Autoinhibitory domains (AIDs)

Target domain

1-1031 (N-terminal region containing three substrate-binding sites)

Relief mechanism

Ligand binding

Assay

Split protein assay

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for O70481

Entry ID Method Resolution Chain Position Source
AF-O70481-F1 Predicted AlphaFoldDB

80 variants for O70481

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3392068037 64 E>* No EVA
rs3392148615 65 S>I No EVA
rs3388587057 130 S>N No EVA
rs3388586344 132 V>I No EVA
rs3388582424 156 A>S No EVA
rs27423157 165 D>E No EVA
rs3388582805 190 A>V No EVA
rs3388579729 192 R>* No EVA
rs3388578014 192 R>I No EVA
rs3388587745 195 P>L No EVA
rs3388583965 211 K>R No EVA
rs3388587076 247 R>K No EVA
rs3388587765 300 V>G No EVA
rs3388579743 337 Q>H No EVA
rs3388582762 395 Y>C No EVA
rs3388576634 445 L>M No EVA
rs3388583960 449 L>S No EVA
rs3388583288 476 I>K No EVA
rs3388587038 477 C>Y No EVA
rs3388580369 478 D>E No EVA
rs3388584202 490 W>* No EVA
rs3392114339 512 M>I No EVA
rs3388578033 519 R>K No EVA
rs3388586322 521 Q>H No EVA
rs3388587085 531 D>N No EVA
rs3388582765 535 A>V No EVA
rs3388583959 539 Q>* No EVA
rs3388576629 562 V>E No EVA
rs3388583314 572 M>L No EVA
rs27438817 639 G>S No EVA
rs3388583896 715 Y>C No EVA
rs3388582733 735 Q>H No EVA
rs3388583311 772 I>N No EVA
rs3388587738 868 P>H No EVA
rs49215462 888 M>I No EVA
rs27438849 888 M>L No EVA
rs3388586374 897 R>W No EVA
rs3388586340 898 A>T No EVA
rs27438850 901 M>T No EVA
rs3388587042 902 E>V No EVA
rs3388583394 910 M>I No EVA
rs235951634 926 K>Q No EVA
rs3392068027 942 Y>F No EVA
rs27438865 964 K>R No EVA
rs51051976 973 S>G No EVA
rs3388576636 1001 T>I No EVA
rs27438871 1008 V>I No EVA
rs29523023 1014 T>S No EVA
rs3391973972 1031 L>P No EVA
rs3392144738 1039 Q>R No EVA
rs3388580315 1062 T>S No EVA
rs261181185 1094 T>I No EVA
rs3392122462 1217 Q>* No EVA
rs3388587078 1314 P>S No EVA
rs3388572837 1341 G>* No EVA
rs3388580327 1355 Q>K No EVA
rs27438903 1357 N>S No EVA
rs27438904 1371 T>A No EVA
rs258221747 1379 H>Q No EVA
rs236768014 1383 A>V No EVA
rs3388583974 1440 L>I No EVA
rs3388582341 1454 I>M No EVA
rs213949529 1462 L>V No EVA
rs46282240 1464 S>P No EVA
rs27438924 1496 A>T No EVA
rs3388580330 1534 E>* No EVA
rs255995843 1542 E>D No EVA
rs3388583552 1561 L>P No EVA
rs3388584214 1566 W>G No EVA
rs3388583352 1576 W>* No EVA
rs3388578035 1584 K>E No EVA
rs3388583949 1592 V>L No EVA
rs3388583911 1642 L>P No EVA
rs3388580368 1672 V>D No EVA
rs3388583894 1686 V>E No EVA
rs3388587045 1724 R>E* No EVA
rs3388583581 1725 K>R No EVA
rs3388586326 1727 H>P No EVA
rs3388579753 1727 H>Y No EVA
rs3388579773 1735 I>N No EVA

No associated diseases with O70481

3 regional properties for O70481

Type Name Position InterPro Accession
domain Myosin head, motor domain 79 - 784 IPR001609
domain Myosin tail 848 - 1928 IPR002928
domain Myosin, N-terminal, SH3-like 31 - 81 IPR004009

Functions

Description
EC Number 2.3.2.27 Aminoacyltransferases
Subcellular Localization
  • Cytoplasm, cytosol
PANTHER Family PTHR21497 UBIQUITIN LIGASE E3 ALPHA-RELATED
PANTHER Subfamily PTHR21497:SF27 E3 UBIQUITIN-PROTEIN LIGASE UBR1
PANTHER Protein Class ubiquitin-protein ligase
protein modifying enzyme
PANTHER Pathway Category No pathway information available

4 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
proteasome complex A large multisubunit complex which catalyzes protein degradation, found in eukaryotes, archaea and some bacteria. In eukaryotes, this complex consists of the barrel shaped proteasome core complex and one or two associated proteins or complexes that act in regulating entry into or exit from the core.
ubiquitin ligase complex A protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity. The complex also contains other proteins that may confer substrate specificity on the complex.

4 GO annotations of molecular function

Name Definition
leucine binding Binding to 2-amino-4-methylpentanoic acid.
ubiquitin protein ligase activity Catalysis of the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S -> X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues.
ubiquitin-protein transferase activity Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y --> Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages.
zinc ion binding Binding to a zinc ion (Zn).

5 GO annotations of biological process

Name Definition
cellular response to leucine Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leucine stimulus.
negative regulation of TOR signaling Any process that stops, prevents, or reduces the frequency, rate or extent of TOR signaling.
protein ubiquitination The process in which one or more ubiquitin groups are added to a protein.
ubiquitin-dependent protein catabolic process The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the protein.
ubiquitin-dependent protein catabolic process via the N-end rule pathway The chemical reactions and pathways resulting in the breakdown of a protein or peptide covalently tagged with ubiquitin, via the N-end rule pathway. In the N-end rule pathway, destabilizing N-terminal residues (N-degrons) in substrates are recognized by E3 ligases (N-recognins), whereupon the substrates are linked to ubiquitin and then delivered to the proteasome for degradation.

5 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
P19812 UBR1 E3 ubiquitin-protein ligase UBR1 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) EV
Q9VX91 Ubr1 E3 ubiquitin-protein ligase UBR1 Drosophila melanogaster (Fruit fly) PR
Q8IWV8 UBR2 E3 ubiquitin-protein ligase UBR2 Homo sapiens (Human) SS
Q8IWV7 UBR1 E3 ubiquitin-protein ligase UBR1 Homo sapiens (Human) SS
Q6WKZ8 Ubr2 E3 ubiquitin-protein ligase UBR2 Mus musculus (Mouse) SS
10 20 30 40 50 60
MADEEMDGAE RMDVSPEPPL APQRPASWWD QQVDFYTAFL HHLAQLVPEI YFAEMDPDLE
70 80 90 100 110 120
KQEESVQMSI LTPLEWYLFG EDPDICLEKL KHSGAFQLCG KVFKSGETTY SCRDCAIDPT
130 140 150 160 170 180
CVLCMDCFQS SVHKNHRYKM HTSTGGGFCD CGDTEAWKTG PFCVDHEPGR AGTTKESLHC
190 200 210 220 230 240
PLNEEVIAQA RRIFPSVIKY IVEMTIWEEE KELPPELQIR EKNERYYCVL FNDEHHSYDH
250 260 270 280 290 300
VIYSLQRALD CELAEAQLHT TAIDKEGRRA VKAGVYATCQ EAKEDIKSHS ENVSQHPLHV
310 320 330 340 350 360
EVLHSVVMAH QKFALRLGSW MNKIMSYSSD FRQIFCQACL VEEPGSENPC LISRLMLWDA
370 380 390 400 410 420
KLYKGARKIL HELIFSSFFM EMEYKKLFAM EFVKYYKQLQ KEYISDDHER SISITALSVQ
430 440 450 460 470 480
MLTVPTLARH LIEEQNVISV ITETLLEVLP EYLDRNNKFN FQGYSQDKLG RVYAVICDLK
490 500 510 520 530 540
YILISKPVIW TERLRAQFLE GFRSFLKILT CMQGMEEIRR QVGQHIEVDP DWEAAIAIQM
550 560 570 580 590 600
QLKNILLMFQ EWCACDEDLL LVAYKECHKA VMRCSTNFMS STKTVVQLCG HSLETKSYKV
610 620 630 640 650 660
SEDLVSIHLP LSRTLAGLHV RLSRLGAISR LHEFVPFDGF QVEVLVEYPL RCLVLVAQVV
670 680 690 700 710 720
AEMWRRNGLS LISQVFYYQD VKCREEMYDK DIIMLQIGAS IMDPNKFLLL VLQRYELTDA
730 740 750 760 770 780
FNKTISTKDQ DLIKQYNTLI EEMLQVLIYI VGERYVPGVG NVTREEVIMR EITHLLCIEP
790 800 810 820 830 840
MPHSAIARNL PENENNETGL ENVINKVATF KKPGVSGHGV YELKDESLKD FNMYFYHYSK
850 860 870 880 890 900
TQHSKAEHMQ KKRRKQENKD EALPPPPPPE FCPAFSKVVN LLSCDVMMYI LRTIFERAVD
910 920 930 940 950 960
MESNLWTEGM LQMAFHILAL GLLEEKQQLQ KAPEEEVAFD FYHKASRLGS SAMNAQNIQM
970 980 990 1000 1010 1020
LLEKLKGIPQ LESQKDMITW ILQMFDTVKR LREKSCLVVA TTSGLECVKS EEITHDKEKA
1030 1040 1050 1060 1070 1080
ERKRKAEAAR LHRQKIMAQM SALQKNFIET HKLMYDNTSE VTGKEDSIME EESTSAVSEA
1090 1100 1110 1120 1130 1140
SRIALGPKRG PAVTEKEVLT CILCQEEQEV KLENNAMVLS ACVQKSTALT QHRGKPVDHL
1150 1160 1170 1180 1190 1200
GETLDPLFMD PDLAHGTYTG SCGHVMHAVC WQKYFEAVQL SSQQRIHVDL FDLESGEYLC
1210 1220 1230 1240 1250 1260
PLCKSLCNTV IPIIPLQPQK INSENAEALA QLLTLARWIQ TVLARISGYN IKHAKGEAPA
1270 1280 1290 1300 1310 1320
VPVLFNQGMG DSTFEFHSIL SFGVQSSVKY SNSIKEMVIL FATTIYRIGL KVPPDELDPR
1330 1340 1350 1360 1370 1380
VPMMTWSTCA FTIQAIENLL GDEGKPLFGA LQNRQHNGLK ALMQFAVAQR TTCPQVLIHK
1390 1400 1410 1420 1430 1440
HLARLLSVIL PNLQSENTPG LLSVDLFHVL VGAVLAFPSL YWDDTVDLQP SPLSSSYNHL
1450 1460 1470 1480 1490 1500
YLFHLITMAH MLQILLTTDT DLSSGPPLAE GEEDSEEARC ASAFFVEVSQ HTDGLAGCGA
1510 1520 1530 1540 1550 1560
PGWYLWLSLR NGITPYLRCA ALLFHYLLGV APPEELFANS AEGEFSALCS YLSLPTNLFL
1570 1580 1590 1600 1610 1620
LFQEYWDTIR PLLQRWCGDP ALLKSLKQKS AVVRYPRKRN SLIELPEDYS CLLNQASHFR
1630 1640 1650 1660 1670 1680
CPRSADDERK HPVLCLFCGA ILCSQNICCQ EIVNGEEVGA CVFHALHCGA GVCIFLKIRE
1690 1700 1710 1720 1730 1740
CRVVLVEGKA RGCAYPAPYL DEYGETDPGL KRGNPLHLSR ERYRKLHLVW QQHCIIEEIA
1750
RSQETNQMLF GFNWQLL